193 related articles for article (PubMed ID: 29107346)
21. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
[TBL] [Abstract][Full Text] [Related]
22. The cost effectiveness of rotavirus vaccination in Iran.
Mousavi Jarrahi Y; Zahraei SM; Sadigh N; Esmaeelpoor Langeroudy K; Khodadost M; Ranjbaran M; Sanjari Moghaddam A; Besharat M; Mosavi Jarrahi A
Hum Vaccin Immunother; 2016 Mar; 12(3):794-800. PubMed ID: 26360331
[TBL] [Abstract][Full Text] [Related]
23. [A cost-effectiveness analysis on universal infant rotavirus vaccination strategy in China].
Sun SL; Gao YQ; Yin J; Zhuang GH
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Feb; 37(2):238-42. PubMed ID: 26917523
[TBL] [Abstract][Full Text] [Related]
24. Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
Kim SY; Sweet S; Slichter D; Goldie SJ
BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh.
Sarker AR; Sultana M; Mahumud RA; Van Der Meer R; Morton A
Hum Vaccin Immunother; 2018 Jan; 14(1):189-198. PubMed ID: 29099653
[TBL] [Abstract][Full Text] [Related]
26. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study.
Villanueva-Uy MET; Lam HY; Aldaba JG; Uy TMZ; Valverde HA; Silva MWT; Mooney J; Clark A; Pecenka C
Vaccine; 2021 Nov; 39(48):7091-7100. PubMed ID: 34753614
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
[TBL] [Abstract][Full Text] [Related]
29. Budget Impact Analysis of Rotavirus Vaccine Adoption in the Childhood Immunization Schedule of Iran.
Azad Z; Teimouri F; Akbarisari A; Esteghamati A; Nikfar S
Value Health Reg Issues; 2019 May; 18():91-96. PubMed ID: 30878901
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand.
Rochanathimoke O; Riewpaiboon A; Praditsitthikorn N; Tharmaphornpilas P; Jiamsiri S; Thavorncharoensap M; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):811-819. PubMed ID: 34008471
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
Abbott C; Tiede B; Armah G; Mahmoud A
Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
[TBL] [Abstract][Full Text] [Related]
32. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
[TBL] [Abstract][Full Text] [Related]
33. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan.
Rheingans R; Anderson JD; Bagamian KH; Laytner LA; Pecenka CJ; Gilani SSA; Ahmed M
Vaccine; 2018 Dec; 36(51):7780-7789. PubMed ID: 30007826
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.
Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Atherly D
Lancet Glob Health; 2021 Jul; 9(7):e942-e956. PubMed ID: 33891885
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of rotavirus vaccination in Turkey.
Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of a routine rotavirus vaccination programme in Indonesia.
Wilopo SA; Kilgore P; Kosen S; Soenarto Y; Aminah S; Cahyono A; Ulfa M; Tholib A
Vaccine; 2009 Nov; 27 Suppl 5():F67-74. PubMed ID: 19931723
[TBL] [Abstract][Full Text] [Related]
37. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
38. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
Kim SY; Sweet S; Chang J; Goldie SJ
BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model.
Alkoshi S; Maimaiti N; Dahlui M
Libyan J Med; 2014; 9(1):26236. PubMed ID: 25499622
[TBL] [Abstract][Full Text] [Related]
40. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC.
Debellut F; Jaber S; Bouzya Y; Sabbah J; Barham M; Abu-Awwad F; Hjaija D; Ramlawi A; Pecenka C; Clark A; Mvundura M
PLoS One; 2020; 15(2):e0228506. PubMed ID: 32023295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
